Hikma Pharmaceuticals Plc (HIK) Downgraded by JPMorgan Chase & Co.

JPMorgan Chase & Co. cut shares of Hikma Pharmaceuticals Plc (LON:HIK) to a neutral rating in a report released on Thursday. The brokerage currently has GBX 2,400 ($29.64) price objective on the stock, up from their prior price objective of GBX 2,100 ($25.94).

A number of other analysts have also weighed in on the company. Numis Securities Ltd lowered Hikma Pharmaceuticals Plc to an add rating and set a GBX 2,350 ($29.02) target price for the company. in a research note on Friday, March 10th. Peel Hunt initiated coverage on Hikma Pharmaceuticals Plc in a research note on Wednesday, January 25th. They issued a buy rating and a GBX 2,340 ($28.90) target price for the company. Citigroup Inc restated a neutral rating on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, November 16th. Jefferies Group LLC raised their target price on Hikma Pharmaceuticals Plc from GBX 2,065 ($25.50) to GBX 2,162 ($26.70) and gave the company a buy rating in a research note on Tuesday, January 17th. Finally, AlphaValue restated a buy rating and issued a GBX 2,431 ($30.02) target price on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, November 30th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of GBX 2,353.67 ($29.07).

Hikma Pharmaceuticals Plc (LON:HIK) opened at 2121.44 on Thursday. The company has a 50-day moving average price of GBX 2,047.69 and a 200 day moving average price of GBX 1,925.38. Hikma Pharmaceuticals Plc has a 52-week low of GBX 1,575.00 and a 52-week high of GBX 2,703.00. The company’s market capitalization is GBX 4.79 billion.

Your IP Address:

The company also recently disclosed a dividend, which will be paid on Thursday, May 25th. Investors of record on Thursday, April 6th will be given a GBX 0.22 ($0.00) dividend. This represents a yield of 0.78%. This is a positive change from Hikma Pharmaceuticals Plc’s previous dividend of $0.21. The ex-dividend date is Thursday, April 6th.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.